Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022

Four new medicines recommended for approval

EMA’s human medicines committee (CHMP) recommended four medicines for approval in the European Union (EU) at its April 2022 meeting.

The CHMP gave a positive opinion for Filsuvez* (birch bark extract) for the treatment of epidermolysis bullosa.

Lunsumio* (mosunetuzumab) received a positive opinion from the CHMP for a conditional marketing authorisation for the treatment of relapsed or refractory (when treatment does not work) follicular lymphoma.

A positive opinion was adopted for Tabrecta (capmatinib) for the treatment of advanced non-small cell lung cancer.

A generic medicine, Pirfenidone AET (pirfenidone), received a positive opinion from the Committee for the treatment of idiopathic pulmonary fibrosis.

Recommendations on extensions of therapeutic indication for seven medicines

The Committee recommended seven extensions of indication for medicines that are already authorised in the EU: Bydureon, Elonva, Keytruda, NovoSeven, Retsevmo, Tecentriq and Yescarta.

Facilitating global access to diabetes treatments

The CHMP has given a recommendation for two diabetes mellitus treatments, Actrapid (insulin human) and Insulatard (insulin human), for use outside the EU.

The two diabetes medicines were submitted to EMA under a regulatory procedure (Article 58 of Regulation (EC) No 726/2004) known as EU-Medicines for all (EU-M4All) that enables the Agency to support global regulatory capacity building and contribute to the protection and promotion of public health beyond the EU. See more details in the news announcement in the grid below.

Re-examination

Following a re-examination, the CHMP confirmed its original recommendation for Tecfidera (dimethyl fumarate), initially adopted on 27 January 2022. See more details in the summary of opinion in the grid below.

Revised opinion

The Committee adopted a revised opinion for Yselty (linzagolix choline) after further safety information emerged during the decision-making process.

Three withdrawals of application

Applications for a marketing authorisation for Aduhelm (aducanumab), Miplyffa (arimoclomol) and Neffy (adrenaline) were withdrawn. Aduhelm, for which a re-examination of a previous negative recommendation was ongoing at the time of withdrawal, was intended for the treatment of Alzheimer’s disease; Miplyffa was intended for the treatment of Niemann-Pick disease type C; and Neffy was intended for the emergency treatment of allergic reactions, including anaphylaxis.

Question-and-answer documents on the withdrawals are available in the grid below.

Start of referral

The CHMP started a review of all available information on the benefits and risks of the cancer treatment Rubraca (rucaparib) in patients with cancer of the ovary, fallopian tubes or peritoneum with a BRCA mutation whose cancer has come back after platinum-based chemotherapy and who can no longer have these medicines. The review follows a planned interim analysis of a post-approval study that raised concerns regarding the benefit of the medicine in this indication. The review is carried out under Article 20 of Regulation (EC) No 726/2004. The CHMP further agreed as a temporary measure that physicians are recommended not to start new patients on rucaparib in the above indication while the review is ongoing. For more information, see the Public Health Communication in the grid below.

Agenda and minutes

The agenda of the April 2022 CHMP meeting is published on EMA's website. Minutes of the March 2022 CHMP meeting will be published in the coming weeks.

CHMP statistics

Key figures from the April 2022 CHMP meeting are represented in the graphic below.

*This product was designated as an orphan medicine during its development. Orphan designations are reviewed by EMA's Committee for Orphan Medicinal Products (COMP) at the time of approval to determine whether the information available to date allows maintaining the medicine’s orphan status and granting the medicine ten years of market exclusivity.